Production and Persistence of Specific Antibodies in COVID-19 Patients with Hematologic Malignancies: Role of Rituximab

In lymphoma patients mean antibody levels and seroconversion rates were lower than in other hematologic malignancies patients, primarily because all nine patients who had received rituximab within six months before COVID-19 failed to produce anti-nucleocapsid and anti-spike-antibody.